Douglas S. Ingram

Doug Ingram has served as president, chief executive officer, and board member since 2017, and CEO and board member since July 2025.

He has no ambiguity about Sarepta’s mission:

“We know why we get up every day and work as hard as we do. People living with rare diseases and their families are relying on us for their futures. The responsibility is awesome but the opportunity to do good is breathtaking.”

Doug has a single-minded focus to make Sarepta the leader in precision genetic medicine and rescue lives devastated by rare genetic disease. “For me, Sarepta is a very special place. It provides each of us an opportunity to be part of something important, to change lives, and to do so by focusing on brilliant science, tenacity and a willingness to challenge convention.”

Doug likes to make clear that Sarepta stands out among biotech organizations. “We’re a commercial stage organization with the resources to bring precision genetic medicine from discovery all the way to the patient.”

Doug’s nearly 30 years in the pharma-biotech world began at Allergan, which he joined in 1996, holding positions of increasing responsibility until being named president in 2013. When Allergan was acquired by Actavis in 2015, he moved on to Chase Pharmaceuticals, serving as president and chief executive officer before coming to Sarepta.

Doug received his JD, summa cum laude, from the University of Arizona and his Bachelor of Science, magna cum laude, from Arizona State University. He serves on the Arrowhead Pharmaceuticals and Relay Therapeutics Board of Directors.